Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

63.15 -0.30 (-0.47%)
Streaming Delayed Price Updated: 9:55 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Expert Ratings For Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72 ↗
PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72. 
Via Investor's Business Daily
News headline image
Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): a strong growth stock preparing for the next leg up?. 
Via Chartmill
News headline image
Sarepta Therapeutics Stock Shows Improved Technical Strength ↗
The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition ↗
Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now. 
Via InvestorPlace
News headline image
NASDAQ:HALO is not too expensive for the growth it is showing. ↗
NASDAQ:HALO stands out as a growth opportunity that won't break the bank. 
Via Chartmill
News headline image
9 Analysts Have This To Say About Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout. 
Via Chartmill
News headline image
In the world of growth stocks, NASDAQ:HALO shines as a value proposition. ↗
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable. 
Via Chartmill
News headline image
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket ↗
Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results. 
Via Benzinga
News headline image
The 3 Best Biotech Stocks to Buy in Q2 2024 ↗
Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2. 
Via InvestorPlace
News headline image
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark ↗
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. 
Via Investor's Business Daily
News headline image
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
News headline image
NASDAQ:HALO, a strong growth stock, setting up for a breakout. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) qualifies as a high growth stock and is consolidating. 
Via Chartmill
News headline image
Breaking Down Halozyme Therapeutics: 7 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Halozyme Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
7 Biotech Stocks to Buy as Sector Rotation Ramps Up ↗
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
Via InvestorPlace
News headline image
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation. ↗
While growth is established for HALOZYME THERAPEUTICS INC (NASDAQ:HALO), the stock's valuation remains reasonable. 
Via Chartmill
News headline image
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
Earnings Preview: Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
Looking for growth without the hefty price tag? Consider NASDAQ:HALO. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
News headline image
Gates Ventures, Mayo Clinic Back Tiny Robot Created By $400M Apple Face ID Inventors To Treat Brain Disease ↗
Michael Shpigelmacher, Founder and CEO of Bionaut Labs, with the company’s micro-robot designed to swim through the central nervous system into the brain to treat disease now on trial in the U.S. 
Via Benzinga
News headline image
NASDAQ:HALO, an undervalued stock with good fundamentals. ↗
Despite its impressive fundamentals, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains undervalued. 
Via Chartmill
News headline image
NASDAQ:HALO, a strong growth stock, setting up for a breakout. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
News headline image
NASDAQ:HALO: good value for what you're paying. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
Earnings Scheduled For February 20, 2024 ↗
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. 
Via Benzinga
News headline image
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients ↗
Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell renal cell carcinoma. Noninferiority compared to IV Opdivo. 
Via Benzinga
News headline image
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation. ↗
In the world of growth stocks, NASDAQ:HALO shines as a value proposition. 
Via Chartmill
News headline image
3 Biotech Stocks to Sell in January Before They Crash and Burn ↗
The biotech industry is one of the most profitable though risky at the same time. Here are three biotech stocks to sell. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.